KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Net Margin (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Net Margin data on record, last reported at 9.06% in Q4 2025.

  • For Q4 2025, Net Margin fell 4631.0% year-over-year to 9.06%; the TTM value through Dec 2025 reached 14.57%, down 907.0%, while the annual FY2025 figure was 36.49%, 1285.0% up from the prior year.
  • Net Margin reached 9.06% in Q4 2025 per ACAD's latest filing, down from 25.77% in the prior quarter.
  • Across five years, Net Margin topped out at 55.37% in Q4 2024 and bottomed at 97.94% in Q1 2022.
  • Average Net Margin over 5 years is 10.89%, with a median of 5.16% recorded in 2021.
  • Peak YoY movement for Net Margin: soared 6162bps in 2023, then tumbled -4631bps in 2025.
  • A 5-year view of Net Margin shows it stood at 32.96% in 2021, then grew by 7bps to 30.53% in 2022, then surged by 165bps to 19.82% in 2023, then soared by 179bps to 55.37% in 2024, then plummeted by -84bps to 9.06% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 9.06% in Q4 2025, 25.77% in Q3 2025, and 15.19% in Q2 2025.